U.S. Markets open in 5 hrs 18 mins
  • S&P Futures

    4,266.50
    -10.25 (-0.24%)
     
  • Dow Futures

    33,897.00
    -66.00 (-0.19%)
     
  • Nasdaq Futures

    13,453.00
    -40.25 (-0.30%)
     
  • Russell 2000 Futures

    1,986.40
    -2.70 (-0.14%)
     
  • Crude Oil

    88.21
    +0.10 (+0.11%)
     
  • Gold

    1,776.70
    0.00 (0.00%)
     
  • Silver

    19.60
    -0.13 (-0.66%)
     
  • EUR/USD

    1.0175
    -0.0005 (-0.0509%)
     
  • 10-Yr Bond

    2.8930
    0.0000 (0.00%)
     
  • Vix

    20.43
    +0.74 (+3.76%)
     
  • GBP/USD

    1.2039
    -0.0013 (-0.1047%)
     
  • USD/JPY

    135.2020
    +0.1120 (+0.0829%)
     
  • BTC-USD

    23,437.15
    -357.24 (-1.50%)
     
  • CMC Crypto 200

    557.36
    -15.45 (-2.70%)
     
  • FTSE 100

    7,501.34
    -14.41 (-0.19%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Seer, Inc.
Seer, Inc.

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter of 2022 on Tuesday, August 9, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio